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Abstract
Background: Although mammary microcalcification is frequently observed and has been associated with poor survival
in patients with breast cancer, the genesis of calcification remains unclear. Carbonic anhydrase I (CA1) has been shown
to promote calcification by catalysing the hydration of CO2. This study aimed to determine whether CA1 was correlated
with microcalcification and with other processes that are involved in breast cancer tumourigenesis.
Methods: CA1 expression in breast cancer tissues and blood samples was detected using western blotting, real-time
PCR, immunohistochemistry and ELISA. Calcification was induced in the cultured 4T1 cell line originating from mouse
breast tumours, using ascorbic acid and β-glycerophosphate. Acetazolamide, a chemical inhibitor of CA1, was also
added to the culture to determine the role of CA1 in calcification. The MCF-7 human breast cancer cell line was treated
with anti-CA1 siRNA and was assessed using a CCK-8 cell proliferation assay, an annexin V cell apoptosis assay, transwell
migration assay and a human breast cancer PCR array. The tag SNP rs725605, which is located in the CA1 locus, was
genotyped using TaqMan® genotyping.
Results: Increased CA1 expression was detected in samples of breast carcinoma tissues and blood obtained from
patients with breast cancer. A total of 15.3 % of these blood samples exhibited a 2.1-fold or higher level of CA1
expression, compared to the average level of CA1 expression in samples from healthy controls. Following the
induction of calcification of 4T1 cells, both the number of calcium-rich deposits and the expression of CA1 increased,
whereas the calcification and CA1 expression were significantly supressed in the presence of acetazolamide. Increased
migration and apoptosis were observed in MCF-7 cells that were treated with anti-CA1 siRNA. The PCR array detected
up-regulation of the androgen receptor (AR) and down-regulation of X-box binding protein 1 (XBP1) in the treated
MCF-7 cells. Significant differences in the allele and genotype frequencies of rs725605 were detected in the cohort of
patients with breast cancer but not in other tumours.
Conclusion: The results of this study suggested that CA1 is a potential oncogene and that it contributes to abnormal
cell calcification, apoptosis and migration in breast cancer.
Keywords: Breast cancer, Microcalcification, Tumourigenesis, Carbonic anhydrase I (CA1), Androgen receptor (AR),
X-box binding protein 1 (XBP1)
Background
Mammary microcalcification is frequently associated
with poor survival, and it occurs in 30 to 50 % of breast
cancer patients [1]. Although the diagnostic value of
microcalcification in patients with breast cancer is of
great importance, the genesis of this calcification
remains unclear. There are two distinct forms of
mammary calcifications: calcium oxalate and hydroxy-
apatite [2, 3]. Hydroxyapatite is also a well-documented
component of bone, and the deposition of it in bone tis-
sue requires the coordinated expression of several bone
matrix proteins, which are synthesised by cells of osteo-
blastic lineage [4]. There has been evidence indicating
that calcium carbonate is involved in initial bone forma-
tion, although mineral deposits are typically comprised
of calcium phosphate and not calcium carbonate [5–7].
CA1 (carbonic anhydrase 1) is a member of the carbonic
anhydrase (CA) family, and it catalyses the reversible
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hydration and dehydration reactions of CO2/H2CO3 [8].
In vitro assays have demonstrated that CA1 not only
enhances hydration reactions but also promotes the for-
mation of CaCO3 [9, 10]. In a recent study, we detected
increased expression of CA1 in Saos-2, a human osteo-
sarcoma cell line, following the induction of calcification
with ascorbic acid and β-glycerophosphate. Following
treatment with acetazolamide, an anti-CA1 drug, both
CA1 expression and the formation of mineralised nod-
ules decreased [11]. Furthermore, overexpression of CA1
was detected in the synovial tissues of patients with an-
kylosing spondylitis, a disease characterised by abnormal
bone formation in the spinal and sacroiliac joints [12].
The gene that encodes CA1 is susceptible to ankylosing
spondylitis [11], and transgenic mice with overexpres-
sion of CA1 exhibited bone fusion in their paws and
spines [13]. These results suggest that CA1 might play
essential roles in bio-mineralisation and new bone
formation.
In the present study, we hypothesised that the up-
regulation of CA1 in breast tumours stimulates calcium
precipitation, similar to what occurs in bone tissue. To
test this hypothesis, calcification was induced in 4T1
cells, which originated from a murine mammary adenocar-
cinoma. Cox et al. recently reported a novel in vitro model
of mammary mineralisation using 4T1 cells [14, 15]. Using
this model, we investigated the involvement of CA1 in
bio-mineralisation and calcification. Additionally, the
effects of CA1 on cell proliferation and cell apoptosis
were investigated in anti-CA1 siRNA-treated MCF-7
cells that originated from human breast cancer, and the
pathogenic pathway was analysed using a PCR array
that contained breast cancer genes. We also used a Taq-
man genotyping method to determine the correlations
between common polymorphisms in the CA1 encoding
gene and breast cancer. In a previous study, we genotyped
13 different tag SNPs in the CA1 gene to determine
whether a potential association existed between the CA1
gene and ankylosing spondylitis, using a custom-designed
Illumina 96-SNP VeraCode microarray (Illumina). We
subsequently performed Taqman genotyping of the tag
SNPs that exhibited significant associations with the
disease in a large cohort of the patients. Both microarray
and Taqman genotyping demonstrated that the allele and
gene frequencies of rs725605 were statistically significantly
associated with patients who had ankylosing spondylitis
[11]. At that time, we tested five SNPs by Taqman geno-
typing, and only rs725605 produced favourable results.
Thus, we continued to genotype this tag SNP to deter-
mine whether the CA1 gene had possible associations
with the various types of tumours that were examined in
the current study. Furthermore, we examined the CA1




In the present study, all of the solid tissue samples and
blood samples that were used were collected from
patients of Shandong Provincial Qianfoshan Hospital
(Jinan, China). The tumour diagnoses were verified
using histological methods, and pathological categorisa-
tions were performed according to the World Health
Organisation (WHO) classification system. All of the
included patients signed informed consent forms, and
this study was approved by the ethics committee of
Shandong Provincial Qianfoshan Hospital (reference
number 2013012). All research involving human subjects
(including human material or human data) that is
reported in the manuscript was conducted in compli-
ance with the Helsinki Declaration.
SNP selection and Taqman genotyping
The tag SNP rs725605 was identified by searching the
HapMap database. This tag SNP was selected on the
basis of linkage disequilibrium patterns that were ob-
served in samples obtained from the Han Chinese popu-
lation of Beijing, who were genotyped as part of the
International HapMap Project. Illumina microarray and
Taqman genotyping assays confirmed the location of tag
SNP rs725605 in the CA1 locus [11].
To determine the potential associations between this
tag SNP and various cancer risks, genotyping was
performed using TaqMan® technology in cohorts of
patients who had breast cancer (n = 285, 285 women,
mean age = 47.65 years old), colon cancer (n = 145, 55
women, mean age = 54.13 years old), oesophageal cancer
(n = 285, 40 women, mean age = 61.20 years old), cer-
vical cancer (n = 190, 190 women, mean age = 52.75 years
old), liver cancer (n = 190, 42 women, mean age =
54.05 years old), lung cancer (n = 190, 56 women, mean
age = 58.17 years old), gastric cancer (n = 285, 71 women,
mean age = 56.83 years old) or rectal cancer (n = 137, 50
women, mean age = 54.61 years old), as well as in healthy
controls (n = 285, 71 women, mean age = 38.42 years old).
Blood samples were collected and stored in Monovette
tubes containing 3.8 % sodium citrate.
Genomic DNA was extracted from whole blood samples
with an Omega E-Z 96 Blood DNA kit (Omega, USA)
according to the manufacturer’s protocol. Genotyping
assays were run on a ViiA 7 DX (Life Technology) and
were evaluated according to the manufacturer’s instruc-
tions. Each reaction was performed in a total volume of
10 μl using the following amplification protocol: denatur-
ation at 95 °C for 10 min, followed by 50 cycles of
denaturation at 95 °C for 15 s and finishing with annealing
and extension at 60 °C for 1 min. The genotype of each
sample was determined by measuring allele-specific fluor-
escence using Taqman Genotyper software, version 1.2
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(Life Technology). Duplicate samples and negative controls
were included to verify the accuracy of the genotyping.
Genotyping quality was evaluated using a detailed qual-
ity control procedure that consisted of a >95 % successful
call rate, duplicate calling of genotypes, internal positive
control samples and Hardy-Weinberg Equilibrium (HWE)
testing. SNPs were analysed for associations by comparing
the MAFs (minor allele frequencies) between cases and
controls. Dominant and recessive models were considered
with respect to the minor allele. Associations of SNPs with
diseases were evaluated using odds ratios (ORs) with 95 %
confidence intervals (CIs). Fisher’s exact test was used
for comparisons between categorical variables. p values
less than 0.05 were considered statistically significant.
Genotypic association was assessed using SHEsis soft-
ware [16]. Multiple-test correction, including genomic-
control correction and Bonferroni’s single-step correc-
tion, was performed using Plink software, version 1.07
(http://pngu.mgh.harvard.edu/purcell/plink/).
Western blot analysis
Breast tissues were collected during galactophore opera-
tions from patients with breast cancer (n = 7, 7 women;
34–64 years old, mean 52) or breast fibroadenoma (n = 7,
7 female subjects; 17–59 years old, mean 35). Two
hundred micrograms of each of the breast cancer tumour
and breast fibroadenoma samples were individually homo-
genised in Cell Lysis Solution (Sigma) and were centri-
fuged at 12,000 × g for 30 min at 4 °C. The supernatants
were collected after centrifugation, and protein concentra-
tions were determined using a BCA protein assay kit
(Pierce). In total, 30 μg of protein were loaded and sepa-
rated by sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE), transferred onto a polyvinylidene
membrane and probed with an anti-human carbonic anhy-
drase 1 antibody (1:1000; Abcam). The antibody was pre-
pared by immunising a goat with carbonic anhydrase I that
was extracted from human erythrocytes. The manufacturer
confirmed that no cross-reactivity existed with other
carbonic anhydrases. The membranes were subse-
quently rinsed with washing solution and incubated
with sheep anti-goat IgG conjugated with peroxidase
(1:500; Sigma-Aldrich) for 30 min. Following a washing
step, the immunosignal was detected using an Enhanced
Chemiluminescence (ECL) Plus kit (Millipore) and was
quantified using ImageQuant software, version 5.2 (GE
Healthcare). Another membrane was prepared using the
same protocol and was probed with an anti-GADPH anti-
body (Santa Cruz) to normalise sample loading.
Immunohistochemistry
Tissue array slides were obtained commercially from
Alenabio (China). The array slides contained 40 different
invasive breast ductal carcinoma and 8 different normal
tissue samples. Clinical data, including the age, sex, clin-
ical pathological diagnosis and origin of every participant,
were provided by the manufacturer. Tissue sections were
deparaffinised and rehydrated using standard procedures.
Prior to the application of the antibodies, the tissue
sections were heated at 95 °C for 10 min in citrate buffer
solution (Sigma) to facilitate antigen recovery, followed by
incubation with an endogenous peroxidase inhibitor
(MaixinBio, China) for 30 min at room temperature. After
washing with PBS buffer, the section was incubated with
anti-CA1 overnight at 4 °C. The CA1 antibody was pre-
pared as described above. The immunoreaction was proc-
essed using the UltraSensitive TM S-P Kit (Maixin-Bio,
China) according to the manufacturer’s instructions. The
immune-reactive signal was visualised using DAB sub-
strate, which stains target proteins yellow. Cell structures
were counterstained with haematoxylin.
Real-time PCR
Breast tissues were collected during galactophore opera-
tions that were performed on patients with breast cancer
(n = 12, 12 women; 31–68 years old, mean 51) or breast
fibroadenoma (n = 12, 12 women; 12–59 years old, mean
33). Total RNA extracts from breast cancer and breast
fibroadenoma tissues were reverse-transcribed using an
RNA PCR Kit (TaKaRa). Real-time PCR was conducted
using a ViiA 7 DX. The relative levels of mRNA expression
were calculated using a comparative threshold cycle (Ct)
method. The relative expression levels of the target gene
were normalised to the relative levels of GAPDH mRNA.
The primer sequences that were used for the amplification
of CA1 and GAPDH are described in Table 1. The reaction
conditions were as follows: 10 s at 65 °C, followed by
40 cycles of 5 s at 60 °C and 10 s at 72 °C and then 30 s at
65 °C. The experiment was performed in triplicate, and the
PCR products were confirmed using a melting curve ana-
lysis. Additionally, real-time PCR was used to verify the
PCR array results. The primer sequences that were used
for the amplification of AR (androgen receptor), GSTP1
(glutathione S-transferase pi 1), PTGS2 (prostaglandin-
endoperoxide synthase 2 [prostaglandin G/H synthase and
Table 1 Prime sequences for real time PCR (5'- > 3')
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cyclooxygenase]), SNAI2 (snail family zinc finger 2) and
XBP1 (X-box binding protein 1) are also shown in
Table 1.
ELISA
Blood samples were collected from patients with breast
cancer (n = 92, 90 women; 22–78 years old, mean 53)
and healthy volunteers (n = 84, 82 women; 23–77 years
old, mean 52). The blood samples were centrifuged at
3000 × g for 10 min at 4 °C to remove debris. The
samples were diluted 5-fold with 0.05 M carbonate-
bicarbonate buffer (pH 9.6) and were used to coat 96-
well ELISA microplates (Costar), followed by overnight
incubation at 4 °C. After a brief washing with PBS con-
taining 0.1 % Tween-20 (PBST), the plates were blocked
with 5 % non-fat dry milk for 1 h at room temperature.
The anti-CA1 antibody was diluted 1000-fold with
PBST and was added to the plate, and the plate was
then incubated for 2 h at room temperature. After
washing with PBST, a 1000-fold dilution of HRP-
conjugated anti-goat total IgG (Sigma) was added, and
the plate was incubated at room temperature for 1 h.
The plates were washed three times and developed
using tetramethyl benzidine (TMB, Sigma) as a sub-
strate. O.D. was measured with a microplate reader at
450 nm.
Cell culture and induction of bio-mineralisation
The 4T1 cell line, which originated from a murine
mammary adenocarcinoma, was maintained in regular
growth media that consisted of low glucose DMEM,
10 % FBS and 1 % penicillin/streptomycin. The cell line
was purchased from the American Tissue Culture
Collection. All of the cell culture reagents were pur-
chased from Sigma-Aldrich. The 4T1 cells were seeded
into 6-well culture plates at a density of 105 cells/well
and were induced for calcification with an osteogenic
cocktail (OC) (50 g/ml ascorbic acid, 10 mM β-
glycerophosphate) the following day. The cells were
maintained in an atmosphere of 37 °C and 5 % CO2,
and half of the medium was replenished every 3 days
until the 28th day. This protocol design was based on a
study by Cox et al. [14, 15].
To verify the effects of CA1 expression on bio-
mineralisation, acetazolamide, a chemical inhibitor of
CA1, was used to treat the 4T1 cells. Acetazolamide
(Sigma) was dissolved in dimethyl sulphoxide (DMSO,
Solabio) at a concentration of 1 % and was added to cell
cultures that were grown to 70 % confluence in OC. The
cultures were grown in the presence of acetazolamide at
a final concentration of 1 mM. The 4T1 cells were also
cultured in OC with 1 % DMSO as a control. The proto-
col was based on a study by Hall et al. [17, 18].
Alizarin Red-S staining and quantification of
bio-mineralisation
The cultured cells were washed with phosphate-buffered
saline (PBS, Solabio) and were stained with 0.5 % (w/v)
Alizarin Red-S (AR-S, Solabio) in PBS (pH = 5.0) for
30 min at room temperature. After being washed four
times with PBS, the stained cells were photographed.
The cultured cells were then de-stained with 10 % (w/v)
cetylpyridinium chloride (Biobasic) in PBS (pH = 7.0)
for 1 h at room temperature. The AR-S concentration
was determined by measuring absorbance at 562 nm.
The protocol was based on previously published studies
[11, 19].
Expression levels of bone sialoprotein (BSP) and osteo-
calcin (OCN), two bone matrix proteins, were deter-
mined using real-time PCR. The expression of CA1 in
the treated 4T1 cells was determined using real-time
PCR and western blot analysis.
Inhibiting CA1 expression with siRNAs in MCF-7 cells
The MCF-7 cell line, which originated from human
breast cancer mammary epithelium, was cultured in
regular growth media that consisted of RPMI-1640, 10 %
FBS and 1 % penicillin/streptomycin. The cell line was
purchased from the American Tissue Culture Collection.
All of the cell culture reagents were purchased from
Sigma-Aldrich. siRNA oligonucleotides targeting CA1
(target mRNA sequence: 5′-TCTACTCTCCTTCCTT
CAT -3′) were designed and synthesised by RIBOBIO.
The cultured MCF-7 cells were transfected with the siR-
NAs at 20 nM using HiPerFect transfection reagent
(Qiagen), according to the manufacturer’s protocol. The
cells were harvested for analysis 72 h after the transfec-
tion. Parallel experiments with AllStars siRNAs, which
was provided with the kit, were used as a negative con-
trol. The AllStars siRNA has no homology to any known
mammalian gene and therefore should not affect any
gene expression. Additionally, the MCF-7 cells that were
transfected with HiPerFect transfection reagent were
also used as a control in the experiment.
Cell proliferation assay
MCF-7 cells were seeded into 96-well culture plates and
incubated until they reached 80 % confluence. The
culture was then treated with anti-CA1 siRNA and incu-
bated for 24–72 h at 37 °C in 5 % CO2. Following the
addition of 10 μl of Cell Counting Kit-8 (CCK-8,
Dojindo) solution to each well, the cells were incubated
for an additional 4 h. Absorbance was measured at 450 nm
with a spectrophotometer (Spectramax 190; Molecular
Devices). Growth curves were generated from the average
values of five wells per group.
The proliferation of the 4T1 cells that were cultured
with OC was measured using the same protocol.
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Cell apoptosis assay
Apoptosis in the siRNA-treated MCF-7 cells was ana-
lysed using flow cytometry (FACSAria II, BD Biosci-
ences). The cultured cells were washed twice with PBS
and were resuspended in binding buffer at a concentra-
tion of 1 × 106 cells/ml. The cell suspensions (1 × 105
cells/100 μl) were transferred into 5 ml culture tubes,
and 5 μl of annexin V-phycoerythrin (eBioscience) and
5 μl of 7-amino-actinomycin (eBioscience) were then
added. The cells were gently vortexed and incubated at
room temperature in the dark for 15 min. Subse-
quently, another 400 μl of aliquot of binding buffer
were added. Flow cytometry was performed within 4 h
of staining.
Transwell migration assay
Transwell inserts (8.0 μm pore size) with a polycarbon-
ate filter (Costar®) were used to examine the effects of
CA1 on cell migration. siRNA-treated MCF-7 cells (5 ×
104 cells/200 μl) were suspended in serum-free media
and added to the upper chamber, and 500 μl of
complete DMEM media were added to the lower cham-
ber. Following incubation for 24 h, the filter was
immersed in methanol for 15 min at room temperature
and then was treated with 0.25 % crystal violet stain for
10 min at room temperature prior to washing with
water. The cells that had migrated to the lower side of
the filter were counted with an inverted fluorescence
microscope.
PCR arrays and data verification
A Human Breast Cancer RT2 Profiler™ PCR Array (Qiagen)
was used to screen for breast tumour genes that were
affected by CA1 expression. The breast cancer pathway
PCR array profiled the expression of 84 different key
genes that are commonly involved in the dysregulation
of signal transduction and other normal biological
processes during breast carcinogenesis. PCR array ana-
lysis was conducted using a ViiA7 DX according to
the manufacturer’s instructions. The procedure begins
with the conversion of experimental RNA samples into
first-strand cDNA using a RT2 First Strand Kit. Subse-
quently, the cDNA is mixed with an appropriate RT2
SYBR Green Mastermix. This mixture is then ali-
quoted into the wells of the RT2 Profiler PCR Array.
Real-time PCR detection was performed under the
following thermal cycling conditions: 95 °C for 10 min,
40 cycles of 95 °C for 15 s and 1 cycle of 60 °C for
1 min. Relative expressions were determined using the
data that were generated with the real-time cycler and
Table 2 Taqman genotyping (rs725605-CA1) result (control n = 288)



















Allele A G A G A G A G A G A G A G A G
Case (freq) 220 (0.396) 118 (0.447) 113 (0.404) 163 (0.455) 252 (0.486) 232 (0.441) 162 (0.435) 174 (0.481)
336 (0.604) 146 (0.553) 167 (0.596) 195 (0.545) 266 (0.514) 294 (0.559) 210 (0.565) 188 (0.519)
Control (freq) 270 (0.475) 270 (0.475) 270 (0.475) 270 (0.475) 270 (0.475) 270 (0.475) 270 (0.475) 270 (0.475)
298 (0.525) 298 (0.525) 298 (0.525) 298 (0.525) 298 (0.525) 298 (0.525) 298 (0.525) 298 (0.525)

















Fisher’s p value 0.0071 0.44502 0.0483 0.55165 0.714 0.255551 0.230431 0.874386
Genotype A/A A/A A/A A/A A/A A/A A/A A/A
A/G A/G A/G A/G A/G A/G A/G A/G
G/G G/G G/G G/G G/G G/G G/G G/G
Case (freq) 49 (0.176) 23 (0.174) 21 (0.150) 38 (0.212) 51 (0.197) 53 (0.202) 33 (0.177) 41 (0.227)
122 (0.439) 72 (0.545) 71 (0.507) 87 (0.486) 150 (0.579) 126 (0.479) 96 (0.516) 92 (0.508)
107 (0.385) 37 (0.280) 48 (0.343) 54 (0.302) 58 (0.224) 84 (0.319) 57 (0.306) 48 (0.265)
Control (freq) 67 (0.236) 67 (0.236) 67 (0.236) 67 (0.236) 67 (0.236) 67 (0.236) 67 (0.236) 67 (0.236)
136 (0.479) 136 (0.479) 136 (0.479) 136 (0.479) 136 (0.479) 136 (0.479) 136 (0.479) 136 (0.479)
81 (0.285) 81 (0.285) 81 (0.285) 81 (0.285) 81 (0.285) 81 (0.285) 81 (0.285) 81 (0.285)
Fisher’s p value 0.029 0.30265 0.1048 0.825315 0.063 0.53125 0.317314 0.820064
HWE for case (df = 1) 0.1697 0.23526 0.527 0.787951 0.01 0.645998 0.497597 0.807632
HWE for control (df = 1) 0.5011 0.50114 0.5011 0.501122 0.501 0.501136 0.501122 0.501122
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the ΔΔCT method. Another PCR array experiment
was prepared with total RNA extracted from the cells
with treatment of Allstars siRNA. The transcription
levels of the target genes were normalised to their
corresponding expression levels in the cells that were
treated with Allstars siRNA. Data analysis was per-
formed using Web-based RT2 Profiler PCR Array Data
Analysis software (http://pcrdataanalysis.sabiosciences.com/
pcr/arrayanalysis.php, SA Biosciences). Fold-changes in
gene expression were calculated and expressed as log-
normalised ratios of the siRNA treated cells/controls.
According to the instructions of the manufacturer, genes
with at least a 4-fold changes in expression were consid-
ered to be biologically significant in the study. The
results of the PCR array assay were confirmed by
performing real-time PCR on RNA extracts from anti-
CA1 siRNA-treated MCF-7 cells.
Statistical analyses
Statistical analyses of the data were performed using SPSS
software, version 16 (SPSS). Multiple comparisons were
conducted using ANOVA. The t-test was conducted to
assess significant differences between two groups. P values
less than 0.05 were considered significant. The data are
presented as standard deviations.
Results
Genotyping rs725605 in cohorts of patients with tumours
Using the TaqMan method, genotyping of the tag SNP
rs725605 was performed in samples obtained from
Fig. 1 CA1 expression in breast cancer and breast fibroadenoma. a Visualisation of CA1 expression and GAPDH expression in breast cancer tissues using
western blot analysis. b Visualisation of CA1 expression and GAPDH expression in breast fibroadenoma using western blot analysis. c For quantification
purposes, the level of CA1 protein expression was normalised against GAPDH expression in each of the tissues. d Quantifying the expression of CA1
mRNA in breast cancer tissue and breast fibroadenoma using real-time PCR; CA1 expression was normalised against GAPDH expression in each of the
tissues. The expression levels are depicted as the means ± SEMs. * indicates p< 0.05, ** indicates p< 0.01, *** indicates p < 0.001
Fig. 2 Immunolocalisation of CA1 expression in breast cancer tissues. a CA1 expression was significantly increased in breast cancer tissue. b CA1
expression was very low in normal breast tissue. The immune signals were located in tumour cells. Original magnification: ×20
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cohorts of patients with breast cancer, colon cancer,
oesophageal cancer, cervical cancer, liver cancer, lung
cancer, gastric cancer, or rectal cancer, in addition to
healthy controls. The allelic and gene frequencies of the
SNP did not deviate from HWE in any of the cohorts. The
allele frequency (OR = 0.722663, 95 % CI = 0.570361–
0.915634, p = 0.007104) and gene frequency (p = 0.029009)
of SNP rs725605 were both statistically associated with
breast cancer. Following multivariate logistic regression
analysis using Plink software, version 1.07, the correlations
between the SNP frequencies and breast cancer were
found to be statistically significant. The genotyping data
did not indicate significant differences in the allelic or
genotypic frequencies of rs725605 (p > 0.05) between
patients with colon cancer, oesophageal cancer, cervical
cancer, liver cancer, lung cancer, gastric cancer or rectal
cancer and healthy controls. The results are shown in
Table 2. SNP rs725605 is located in the intron 1 region of
the gene that encodes CA1.
Expression of CA1 in breast cancer tissues
Western blot analysis was performed to detect the
expression of CA1 in breast tumour tissue and breast
fibroadenoma. Using GAPDH as a reference, western blot-
ting revealed that the expression of CA1 was significantly
increased in the breast cancer samples, compared to the
breast fibroadenoma samples (p = 0.008). Six of seven of
the breast cancer samples exhibited increased levels of ex-
pression. Only two of seven of the breast fibroadenoma
samples exhibited relatively high CA1 expression. These
results are shown in Fig. 1.
The transcription of CA1 was also examined using real-
time PCR. Similar to the western blotting results above,
the breast cancer samples (n = 12) exhibited a higher
degree of CA1 mRNA expression than the breast fibro-
adenoma tissue samples (n = 12; p = 0.0000525). These
results are shown in Fig. 1.
Fig. 3 The detection of CA1 levels in patient blood samples using ELISA. The levels of CA1 are represented by O.D. values, which were measured
at 405 nm. The results are expressed as the means ± SEMs. * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001
Fig. 4 Inducing calcification in 4T1 cells with ascorbic acid and
β-glycerophosphate. 4T1 cells were incubated in normal media (control)
and an osteogenic cocktail (OC). a The cell cultures were stained with
AR-S to detect calcium nodules and were photographed at the original
magnification and at ×100 magnification. b The cell cultures were
stained with cetylpyridinium chloride and were quantified by measuring
the absorbance at 562 nm. * indicates p< 0.05, ** indicates p< 0.01,
*** indicates p < 0.001
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Immunohistochemistry was performed to visualise
CA1 expression in a panel of breast tumour tissues.
There was significant expression of CA1 in 39 of 40
(97.5 %) of the invasive breast ductal carcinomas. There
was no obvious expression of CA1 in normal breast
tissue except for in select mesenchymal-like cells and
select endothelial cells. The immunosignals were local-
ised in the cytoplasm of breast tumour cells. The immu-
nohistochemical results are shown in Fig. 2.
CA1 levels in blood samples obtained from patients with
breast cancer
Sandwich ELISA was used to measure the levels of CA1
in the blood samples that were obtained from patients
with breast cancer. There were significantly increased
Fig. 5 Analysis of cell proliferation using CCK-8 assay. 4T1 cells were incubated in either normal culture media (control) or osteogenic medium (OC).
The numbers of viable cells are represented by O.D. values, which were measured at 492 nm. The error bars represent the standard deviation from five
repeated measurements. * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001
Fig. 6 Detecting the mRNA expression of BSP and OCN in 4T1 cells
using real-time PCR analysis. 4T1 cells were incubated with an
osteogenic cocktail (OC). These cells, which were cultured in
normal media, were used as a control. a BSP mRNA expression.
b OCN mRNA expression. The expression was normalised to the
expression of GAPDH. * indicates p < 0.05, ** indicates p < 0.01,
*** indicates p < 0.001
Fig. 7 CA1 expression in the calcified 4T1 cells. a CA1 transcription
was detected using real-time PCR in 4T1 cells that were treated with
osteogenic cocktail (OC). b CA1 protein expression in 4T1 cells
treated with OC was detected using western blot analysis. c The
protein expression level was normalised to the expression of GAPDH.
* indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001
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levels of CA1 in the samples that were obtained from
breast cancer patients (OD average = 0.91 ± 0.46) compared
to the samples that were obtained from healthy controls
(OD average = 0.55 ± 0.3). Fourteen of 92 (15.22 %) of the
samples that were obtained from patients with breast
cancer exhibited two-fold or greater expression of CA1,
compared to the average level of expression that was mea-
sured in the samples that were obtained from healthy
controls. Only one sample from the healthy control group
(1.19 %) exhibited a higher level of CA1 expression than
the average level in the healthy samples. The serum levels
of CA1 were significantly different between breast cancer
patients and healthy controls (p = 9.18 × 10−5). The ELISA
results are shown in Fig. 3.
Bio-mineralisation, cell proliferation and expression of
CA1, BSP and OCN in 4T1 cells
Following the induction of bio-mineralisation with OC,
numerous calcium deposits were observed in cultured
4T1 cells after incubations of 7, 14, 21 and 28 days. The
absorbance of cetylpyridinium chloride was 1.64-fold
higher in 4T1 cells that were incubated with OC for
7 days than in cells that were cultured without induction
(p = 4.32 10−6), and it was 2.57-fold higher at 14 days
(p = 2.04 × 10−12), 4.46-fold higher at 21 days (p = 6.05 ×
10−16), and 6-fold higher at 28 days (p = 7.87 × 10−13).
These results are shown in Fig. 4.
4T1 cells were incubated with OC for 2 and 3 days,
and viable cells were detected using CCK-8 assay. There
Fig. 8 Inhibiting calcification in 4T1 cells with acetazolamide. The 4T1 cells were incubated with osteogenic cocktail (OC) supplemented with
1 mM acetazolamide (AZ). a The 4T1 cells cultured with OC supplemented with DMSO in the presence or absence of AZ were stained with AR-S
and were photographed at the original magnification and at ×100 magnification. b The 4T1 cells, cultured with OC supplemented with DMSO in
the presence or absence of AZ, were stained with cetylpyridinium chloride and were quantified by measuring their absorbance at 562 nm. c CA1
transcription in 4T1 cells was detected by real-time PCR. d CA1 protein expression in 4T1 cells was detected using western blot analysis. e The
protein expression level was normalised to the expression of GAPDH. * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001
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were no significant differences in the numbers of viable
cells that were detected between the 4T1 cells that were
cultured in OC and those that were cultured in normal
media at either 2 days (p = 0.875) or 3 days (p = 0.116).
These results are shown in Fig. 5.
The level of BSP mRNA was 4.68-fold (p = 2.57 × 10−8)
higher in the OC-stimulated 4T1 cells than in the cells
without stimulation, and OCN increased by 5.67-fold
(p = 3.01 × 10−5) when 4T1 cells were incubated in OC
for 28 days. These results are shown in Fig. 6. The
increased expression of BSP and OCN indicated that
the 4T1 cells that were incubated in OC underwent
ossification.
The transcription and translation of CA1 in the OC-
stimulated cells were measured using real-time PCR and
western blotting, respectively. The level of CA1 mRNA
was significantly elevated in the OC-stimulated cells
compared with the controls (p = 0.00752) after 28 days
in culture. The translation of CA1 in the OC-stimulated
cells was also significantly increased compared with the
controls (p = 0.0295). These results are shown in Fig. 7.
To identify the essential role of CA1 for calcification
in breast cancer cells, acetazolamide, a chemical inhibi-
tor of CA1, was added into the culture medium when
4T1 cells were induced to produce calcification with
OC. Compared with 4T1 cells that were treated with OC
in the presence of DMSO, the formation of calcium
nodules was significantly decreased in the cells cultured
with OC in presence of DMSO and acetazolamide for
14, 21 and 28 days. Because acetazolamide was dissolved
only in DMSO, the cells cultured with OC supplemented
with DMSO were used as a control in the experiment.
The absorbance of cetylpyridinium chloride was also
considerably decreased in 4T1 cells that were treated
with acetazolamide for 14 days (p = 0.038), 21 days
(p = 0.012) and 28 days (p = 0.007). This experiment
was repeated three times, obtaining similar results.
The results are shown in Fig. 8.
Suppressing CA1 expression in MCF-7 cells using siRNA
MCF-7 cells were transfected with siRNA targeted to
CA1. The transcription and translation of CA1 in the
treated cells were measured using real-time PCR and
western blotting, respectively. Following the anti-CA1
siRNA treatment, both the transcription (p = 0.004) and
the translation (p = 0.0003) of CA1 were considerably
reduced in the siRNA-treated MCF-7 cells, compared
with the cells that were treated with the Allstars siRNA
negative control and the cells that did not receive siRNA
treatment. Neither the control nor negative control
siRNA led to a significant change in the expression of
CA1 mRNA, indicating the specificity of the RNA inter-
ference with regard to CA1 expression in this experi-
ment. These results are shown in Fig. 9.
The proliferation of MCF-7 cells that were treated
with anti-CA1 siRNA was measured using CCK-8 assay.
No significant change in cell proliferation was detected
in the siRNA-treated MCF-7 cells, compared to the
cells that were treated with the negative siRNA control
(p = 0.981) and the cells that were treated only with
HiPerFect transfection reagent (p = 0.801). These re-
sults, which are shown in Fig. 10, indicated that CA1
did not affect MCF-7 cell proliferation.
The effect of CA1 on apoptosis in MCF-7 cells was
determined using flow cytometric analysis with annexin
V/PE and 7-AAD double staining. Compared with the
negative control (5.57 ± 0.15 %), the number of apoptotic
cells was significantly increased in the anti-CA1 siRNA-
treated cells (p = 9.14E-8). No significant differences
Fig. 9 CA1 expression in anti-CA1 siRNA-treated MCF-7 cells. a The
expression of CA1 mRNA was detected using real-time PCR. b The
level of CA1 protein expression was detected using western blot
analysis. c The level of CA1 protein expression was normalised against
the expression of GAPDH. The cells without siRNA treatment were
used as controls, and the cells treated with Allstars siRNA were
used as negative controls. * indicates p < 0.05, ** indicates p < 0.01,
*** indicates p < 0.001
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were detected between the control and negative control
groups (p = 0.547). These results, shown in Fig. 11,
demonstrate that down-regulation of CA1 expression
could induce apoptosis in MCF-7 cells.
MCF-7 cell migration was examined using a 2-
compartment transwell system. MCF-7 cell migration in-
creased significantly when CA1 expression was suppressed
by anti-CA1 siRNA (p < 0.001). No significant difference
in migration was observed between the control cells and
the cells that were treated with negative control siRNA
(p > 0.05). These results are shown in Fig. 12.
To identify the details of CA1’s involvement in breast
cancer tumourigenesis, a PCR array containing 84 differ-
ent breast cancer-related genes was used to compare the
expression profiles of MCF-7 cells that exhibited down-
regulated CA1 expression and MCF-7 cells that were
treated with AllStars siRNA. Five different breast cancer-
related genes exhibited significantly different expression
patterns (4-fold or greater changes) in anti-CA1 siRNA-
treated MCF-7 cells. The expression of AR (androgen
receptor) gene expression was up-regulated, whereas the
expression of the GSTP1 (glutathione S-transferase pi 1),
PTGS2 (prostaglandin-endoperoxide synthase 2), SNAI2
(snail family zinc finger 2) and XBP1 (X-box binding
protein 1) genes was down-regulated in the cells. These
results are shown in Additional file 1 and Fig. 13a.
The results of the PCR array were verified with real-
time PCR. Compared with the AllStars siRNA-treated
MCF-7 cells, the average expression level of AR was
significantly elevated (p < 0.001), and the average expres-
sion level of XBP1 was significantly reduced (p < 0.01) in
the anti-CA1 siRNA-treated MCF-7 cells. No signifi-
cantly different expression patterns in the GSTP1,
PTGS2, or SNAI2 genes were detected in the CA1-
siRNA cells. The real-time PCR results are shown in
Fig. 13b.
Discussion
Despite the diagnostic and potential prognostic value of
microcalcification, the mechanisms underlying the forma-
tion and functional role of microcalcification in breast
cancer progression remain unclear. In the present study,
we genotyped Tag SNP rs725605 in cohorts of patients
with various types of tumours and found that this tag
SNP, which is located in the intron 1 region of the gene
that encodes CA1, was strongly associated with breast
cancer but with no other tumours. The results suggested
that CA1 is a risk factor for breast cancer. Additionally,
increases in CA1 transcription and translation were
detected in breast cancer tissue compared to breast fibro-
adenoma tissue via western blot and RT-PCR analysis.
Benign breast lesions exhibit calcification similar to breast
cancer tissues. Thus, it was feasible in this study to use
fibroadenoma breast tissue as a control when studying
calcification in breast tumours [20]. Using immunohisto-
chemistry, extensive expression of CA1 was detected in
breast cancer tissues but not in normal tissues. Further-
more, ELISA indicated that the levels of CA1 were signifi-
cantly increased in several of the blood samples that were
obtained from patients with breast cancer. These results
suggested that increased CA1 expression might play a role
in breast cancer tumourigenesis.
In the current study, we aimed to identify the role of
CA1 in mammary calcification by inducing mineralisa-
tion of 4T1 cells. Following stimulation with ascorbic
acid and β-glycerophosphate, numerous calcium-rich
deposits were produced in 4T1 cells, and the transcrip-
tion levels of osteogenesis-related genes, including BSP
and OCN, were significantly increased, indicating that
the cells underwent calcification and ossification. CA1 ex-
pression was significantly increased in the OC-stimulated
cells during calcification. In addition, the OC did not
significantly increase cell proliferation. Thus, the observed
Fig. 10 Proliferation of MCF-7 cells that were treated with anti-CA1 siRNA, as measured by CCK-8 assay. Viable cell numbers are represented by
an O.D. value that was measured at 405 nm. The cells without siRNA treatment were used as controls, and the cells treated with Allstars siRNA
were used as negative controls. *indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001
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increase in mineralisation was due to a direct effect on
mineralisation, rather than because of increased cell num-
bers. The expression levels of CA1 and calcification were
significantly decreased when the cells were incubated with
acetazolamide, a chemical inhibitor of CA1. These results
suggested that increased expression of CA1 promotes the
calcification of breast cancer. We knocked down CA1
expression in MCF-7 cells using siRNA. The down-
regulation of CA1 expression significantly stimulated cell
apoptosis and cellular migration but did not influence cell
proliferation, consistent with what was observed in 4T1
cells that were subjected to an induction of calcification.
These results suggested that CA1 expression also mediates
apoptosis and cell migration, which are two important
steps in the process of tumourigenesis.
The pathogenic pathway of CA1 in breast cancer
tumourigenesis was investigated using a PCR array that
contained 84 different breast cancer-related genes. The
results were verified with real-time PCR. The assay
detected increased expression of the AR gene and de-
creased expression of the XBP1 gene in MCF-7 cells fol-
lowing anti-CA1 siRNA treatment, suggesting that CA1
functions by regulating the expression of AR and XBP1.
AR expression has been reported in approximately
80 % of primary breast cancers [21]. Hu et al. reported
that a significant reduction in breast cancer mortality
was associated with AR expression in patients with ER
(oestrogen receptor) + cancers [22]. Other groups have
also reported that AR expression was associated with
favourable outcomes in patients with ER+ breast cancers
Fig. 11 Apoptosis in MCF-7 cells that were treated with anti-CA1 siRNA, as measured using an annexin V cell apoptosis assay. (a) The cells with-
out siRNA treatment were used as controls. (b) The cells treated with Allstars siRNA were used as negative controls. (c) The cells were treated with
anti-CA1 siRNA. (d) The result of apoptosis assay is shown in a graph. *indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001.
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[22-24]. Yeh et al. suggested that AR might play a
positive role in promoting breast cancer progression
[25]. Additionally, Venken et al. demonstrated that AR-
knockout mice exhibited reduced bone size and cortical
thickness and decreased trabecular bone volume [26].
Androgen/AR signalling plays an essential role in bone
formation by coordinating the expression of genes that
are associated with phosphate regulation [25-27]. Our
results revealed that inhibiting CA1 expression could in-
crease the expression of AR, suggesting that CA1 could
regulate AR expression and might therefore influence
the progression of microcalcification and other tumouri-
genic processes during breast cancer tumourigenesis.
XBP1 is a transcription factor that belongs to the basic
region/leucine zipper (bZIP) family [28]. The XBP1 protein
is expressed in almost 80 % of ER+ breast tumours. The
overexpression and splicing of XBP1 have been associated
with poor outcomes in breast cancer patients [29]. XBP1 is
downstream of NFκB, which regulates cell survival via acti-
vation of the anti-apoptotic BCL2 (B-cell lymphoma 2)
gene, as well as several other genes that are associated with
control of the cell cycle and apoptosis [30]. Additionally,
XBP1 signalling increases the expression of Runx2, which
modulates calcification in human coronary artery smooth
muscle cells [31]. The present study found that decreased
expression of CA1 led to decreased expression of XBP1,
consistent with previous studies. This finding suggested
that CA1 enhances XBP1 gene expression, thereby contrib-
uting to calcification and disrupted apoptosis in breast can-
cer cells.
Our study indicated that the down-regulation of CA1
expression significantly stimulated cell apoptosis, but it
did not influence cell proliferation in MCF-7 cells. We
also found that the expression of XBP1 was decreased in
the anti-CA1 siRNA-treated MCF-7 cells. XBP1 can ac-
tivate the anti-apoptotic BCL2 gene [30]. Thus, it is pos-
sible that the decreased CA1 expression in the cultured
breast cancer cells suppressed the anti-apoptotic role of
BCL2, resulting in increased levels of apoptosis in the
treated cells. Apoptosis is not always correlated with cell
proliferation. For example, Gálfi et al. investigated a set
of cell lines to assess their sensitivity to proliferation
inhibition in response to the core histone deacetylase
inhibitors butyrate and trichostatin A. They found that
there was no correlation between sensitivity to prolifera-
tion inhibition and sensitivity to apoptosis induction
with respect to the histone deacetylase inhibitors [32].
Increased migration and apoptosis were observed in
the anti-CA1 siRNA-treated MCF-7 cells, as well as an
increased expression of AR. Numerous studies have
Fig. 12 Migration of MCF-7 cells that were treated with anti-CA1 siRNA, as measured using a transwell migration assay. (a) The cells without siRNA treatment
were used as controls. (b) The cells treated with Allstars siRNA were used as negative controls. (c) The cells were treated with anti-CA1 siRNA. (d) The result of
migration measurement is shown in a graph. Original magnification: x4.2. * indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001.
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reported that AR stimulated tumour cell migration, such
as during prostate cancer cell invasion and oesophageal
cancer cell migration [33,34]. Apoptosis is disrupted
during the progression of many types of solid tumours.
In contrast, apoptosis is not always negatively correlated
with tumourigenic progression, especially in cases of me-
tastasis. For example, Termuhlen et al. reported that iso-
genic metastatic colon adenocarcinoma cells displayed
significantly higher levels of staurosporine-induced apop-
tosis than their nonmetastatic counterparts in vitro [35].
They suggested that the molecular events that were asso-
ciated with the development of a metastatic phenotype
sensitised the tumour cells to selecting pro-apoptotic
stimuli.
In the present study, we induced calcification in the
4T1 cell line to determine whether a correlation existed
between CA1 and bio-mineralisation because Cox et al.
established an excellent in vitro model of mammary
mineralisation using this cell line. However, 4T1 is
mouse cell line; therefore, it might not be physiologically
relevant to human breast cancer. Thus, we also investi-
gated CA1 transcription and translation in MCF-7 cells,
which originated from human breast tumour epithelium.
MCF-7 cells have been reported to express alkaline
phosphatase and bone sialoprotein, both of which
enhance bone mineralisation and calcification [36, 37].
Thus, MCF-7 cells could be induced to produce calcifi-
cation. Carbonic anhydrases catalyse the rapid inter-
conversion of carbon dioxide and water into bicarbonate
and protons, respectively, which can affect physiological
processes in cells by altering pH, proton concentrations,
and membrane permeability. In addition, calcium hy-
droxyapatite has been reported to promote mitogenesis
and matrix metalloproteinase expression in varying
human breast cancer cell lines [38].
Conclusion
This study demonstrated that CA1 expression was in-
creased in samples of breast cancer tissues and blood
obtained from patients with breast cancer. CA1 plays im-
portant roles in the calcification, apoptosis and migration of
tumour cells and contributes to breast cancer tumourigen-
esis by regulating the expression of AR and XBP1.
Additional file
Additional file 1: Human Breast Cancer RT2 Profiler™ PCR array
analysis of gene expression patterns in anti-CA1 siRNA-treated
MCF-7 cells. (a) The expression patterns of 84 different genes related to
breast cancer tumourigenesis were measured. Fold-change values greater
than one indicated a positive finding or up-regulation. Fold-change
values less than one indicated a negative finding or down-regulation.
Fold-change values greater than 2 are indicated in red; fold-change
values less than 0.5 are indicated in blue. (b) A table indicates expression
levels of the 84 different genes. Comments with “A” indicate that the
average threshold cycle of the gene expression is relatively high (>30) in
either the control or the test sample and is reasonably low in the other
sample (< 30). These data indicate that the gene expression is relatively
low in one sample and reasonably detected in the other sample, sug-
gesting that the actual fold-change value is at least as large as the calcu-
lated and reported fold-change results. This fold-change result might also
have greater variations if the p value > 0.05. Comments with “B” indicate
that the average threshold cycle of the gene expression is relatively high
(> 30), indicating that its relative expression level is low in both control
and test samples, and the p value for the fold-change is either unavail-
able or relatively high (p > 0.05). This fold-change result might also have
greater variations. Comment with “C” indicates that the average threshold
cycle of the gene expression is either not determined or greater than the
defined cut-off value (default 35) in both samples, indicating that its ex-
pression was undetected, thus rendering this fold-change result errone-
ous and un-interpretable.
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